Idexx Laboratories (IDXX) Operating Income (2009 - 2026)

Idexx Laboratories has reported Operating Income for 18 years, with the latest figure at $425.6 million in Q2 2026.

• On a quarterly basis, Operating Income rose 14.08% year-over-year to $425.6 million in Q2 2026; TTM through Jun 2026 was $1.5 billion, a 16.21% increase from a year earlier, with the FY2025 full-year figure at $1.4 billion, up 20.53% from the prior year.
• Operating Income was $425.6 million for Q2 2026 at Idexx Laboratories, up from $362.6 million in the prior quarter.
• The five-year high for Operating Income was $425.6 million in Q2 2026, with the low at $179.1 million in Q2 2022.
• Average Operating Income over 5 years is $292.9 million, with a median of $288.3 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2023: Operating Income tumbled 30.93% in 2022, then surged 65.38% in 2023.
• Over 5 years, Operating Income stood at $226.5 million in 2022, then increased by 8.29% to $245.3 million in 2023, then advanced by 6.68% to $261.7 million in 2024, then grew by 20.6% to $315.6 million in 2025, then jumped by 34.84% to $425.6 million in 2026.
• The last three Operating Income figures came in at $425.6 million (Q2 2026), $362.6 million (Q1 2026), and $315.6 million (Q4 2025), per Business Quant data.